The deal, which adds the biosimilar Cimerli (ranibizumab-eqrn) to Sandoz's portfolio, includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

Sandoz and Coherus entered into the transaction agreement in January 2024.

Keren Haruvi, president Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Cimerli, is an anti-VEGF therapy, is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss.